Conversely, the absence of TRAIL or the activation of PP2A can reverse these effects and enhance lung function, suggesting that the E3 ubiquitin ligase MID1 may serve as a viable target for IPF treatment. This evidence concerns the gene PRKN and idiopathic pulmonary fibrosis.